{
    "nctId": "NCT06654570",
    "briefTitle": "Effects of Vaginal Estrogen on Serum Estradiol During Aromatase Inhibitor Therapy in Breast Cancer Patients with Vulvovaginal Atrophy: a Prospective Trial",
    "officialTitle": "Effects of Vaginal Estrogen on Serum Estradiol During Aromatase Inhibitor Therapy in Breast Cancer Patients with Vulvovaginal Atrophy: a Prospective Trial",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Serum estradiol level",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Eligible patients were postmenopausal women (\\> 50 years old) with early-stage hormone receptor-positive BC treated with adjuvant letrozole for at least six months and developed symptoms of AV during this period.\n\nExclusion Criteria:\n\n* Exclusion criteria included premenopausal status, recent use of local estrogen therapy within the previous three months, irregular use of letrozole, and metastatic disease.",
    "sex": "FEMALE",
    "minimumAge": "51 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}